Merck, Sharp & Dohme (MSD; NYSE: MRK) has released long-term effectiveness data for its recombinant human papillomavirus (HPV) 9-valent vaccine, Gardasil 9, in minors aged between 9 and 15 years old. The results indicate that the immunogenicity generated by the vaccine persisted for 10 years after the third and final dose, peaking at month 7 post-vaccination. Notably, no HPV-related genital warts or cancers were observed in either gender throughout the study period.
Safety and Efficacy Profile of Gardasil 9
The study also reported that there were no serious adverse events (SAEs) or deaths related to the vaccine. This finding further reinforces the safety profile of Gardasil 9, which is already known for its effectiveness in preventing HPV-related diseases.
Implications for HPV Vaccination Programs
These 10-year effectiveness data are significant for HPV vaccination programs globally, as they provide evidence of the long-term protection offered by Gardasil 9. This information is crucial for healthcare providers, policymakers, and parents, as it supports the continued use of the vaccine in adolescents to prevent HPV-related cancers and diseases.-Fineline Info & Tech
